0001022079-26-000043
SEC filingQuest Diagnostics delivered solid Q1 results with revenue up 9.2% to $2.9B and operating income rising 15.3% to $399M, driven by organic growth and operating leverage from productivity improvements despite cost pressures.
Gross profit increased 9.2% to $942 million, maintaining a stable gross margin of 32.5%. This resilience occurred despite higher compensation costs and, to a lesser extent, elevated supplies expense. These pressures were partially offset by cost savings and productivity improvements from the Invigorate program, enabling efficient scaling of high-volume routine testing.
Operating income advanced 15.3% to $399 million, with operating margin expanding to 13.8%. The improvement reflects operating leverage, as revenue growth outpaced expense increases. Selling, general, and administrative expenses consist of sales and marketing, billing operations, credit loss, and general management costs. General corporate activities include amortization of intangibles and other operating items. These dynamics underscore disciplined cost management amid inflation.
Net income rose 14.5% to $252 million, translating to diluted EPS of $2.24, up 15.5% from $1.94. This earnings growth highlights the benefits of top-line momentum and margin expansion for shareholders.
Overall, these results demonstrate Quest Diagnostics' ability to drive organic growth, leverage productivity initiatives, and generate cash to sustain operations and returns, positioning the company well amid competitive diagnostics landscape.